Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection

SH Safiabadi Tali, JJ LeBlanc, Z Sadiq… - Clinical microbiology …, 2021‏ - journals.asm.org
SUMMARY The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory disease coronavirus 2 (SARS-CoV-2), has led to millions of confirmed cases and …

[HTML][HTML] Adaptive immunity to SARS-CoV-2 and COVID-19

A Sette, S Crotty - Cell, 2021‏ - cell.com
The adaptive immune system is important for control of most viral infections. The three
fundamental components of the adaptive immune system are B cells (the source of …

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

JM Carreño, H Alshammary, J Tcheou, G Singh… - Nature, 2022‏ - nature.com
Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …

Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses

MG Alameh, I Tombácz, E Bettini, K Lederer… - Immunity, 2021‏ - cell.com
Adjuvants are critical for improving the quality and magnitude of adaptive immune
responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified …

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

F Muecksch, Z Wang, A Cho, C Gaebler, T Ben Tanfous… - Nature, 2022‏ - nature.com
The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent
individuals,–. Despite the reduced protection from infection, individuals who received three …

Long COVID in a prospective cohort of home-isolated patients

B Blomberg, KGI Mohn, KA Brokstad, F Zhou… - Nature medicine, 2021‏ - nature.com
Long-term complications after coronavirus disease 2019 (COVID-19) are common in
hospitalized patients, but the spectrum of symptoms in milder cases needs further …

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Z Wang, F Muecksch, D Schaefer-Babajew, S Finkin… - Nature, 2021‏ - nature.com
More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult …

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses

T Mao, B Israelow, MA Peña-Hernández, A Suberi… - Science, 2022‏ - science.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
highlighted the need for vaccines that not only prevent disease but also prevent …

[HTML][HTML] Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

S Afkhami, MR D'Agostino, A Zhang, HD Stacey… - Cell, 2022‏ - cell.com
The emerging SARS-CoV-2 variants of concern (VOCs) threaten the effectiveness of current
COVID-19 vaccines administered intramuscularly and designed to only target the spike …

[HTML][HTML] SARS-CoV-2-infection-and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase

K Srivastava, JM Carreño, C Gleason, B Monahan… - Immunity, 2024‏ - cell.com
It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies …